VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 94 filers reported holding VERONA PHARMA PLC in Q1 2023. The put-call ratio across all filers is 1.24 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $895,327 | -32.6% | 54,928 | -12.6% | 0.00% | -50.0% |
Q2 2023 | $1,328,120 | -5.4% | 62,825 | -10.1% | 0.00% | 0.0% |
Q1 2023 | $1,403,612 | +8.0% | 69,901 | +40.5% | 0.00% | 0.0% |
Q4 2022 | $1,300,020 | +176.0% | 49,752 | +7.9% | 0.00% | +100.0% |
Q3 2022 | $471,000 | +2843.8% | 46,095 | +1100.4% | 0.00% | – |
Q2 2022 | $16,000 | -15.8% | 3,840 | 0.0% | 0.00% | – |
Q1 2022 | $19,000 | -26.9% | 3,840 | 0.0% | 0.00% | – |
Q4 2021 | $26,000 | +23.8% | 3,840 | 0.0% | 0.00% | – |
Q3 2021 | $21,000 | -16.0% | 3,840 | 0.0% | 0.00% | – |
Q2 2021 | $25,000 | -21.9% | 3,840 | 0.0% | 0.00% | – |
Q1 2021 | $32,000 | +18.5% | 3,840 | 0.0% | 0.00% | – |
Q4 2020 | $27,000 | +12.5% | 3,840 | 0.0% | 0.00% | – |
Q3 2020 | $24,000 | +33.3% | 3,840 | 0.0% | 0.00% | – |
Q2 2020 | $18,000 | +12.5% | 3,840 | 0.0% | 0.00% | – |
Q1 2020 | $16,000 | -27.3% | 3,840 | 0.0% | 0.00% | – |
Q4 2019 | $22,000 | +22.2% | 3,840 | 0.0% | 0.00% | – |
Q3 2019 | $18,000 | -10.0% | 3,840 | 0.0% | 0.00% | – |
Q2 2019 | $20,000 | -20.0% | 3,840 | 0.0% | 0.00% | – |
Q1 2019 | $25,000 | -28.6% | 3,840 | 0.0% | 0.00% | – |
Q4 2018 | $35,000 | -27.1% | 3,840 | 0.0% | 0.00% | – |
Q3 2018 | $48,000 | -7.7% | 3,840 | 0.0% | 0.00% | – |
Q2 2018 | $52,000 | -32.5% | 3,840 | 0.0% | 0.00% | – |
Q1 2018 | $77,000 | – | 3,840 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |